Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BI 764198 in Subjects With Moderate and Severe Renal Impairment in Comparison to Subjects With Normal Renal Function (a Mono-centric, Open-label Study With Matched-pair Design)
Latest Information Update: 04 Nov 2021
At a glance
- Drugs BI 764198 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 17 Dec 2020 Status changed from active, no longer recruiting to completed.
- 18 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2020 Planned End Date changed from 24 Nov 2020 to 17 Nov 2020.